Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:52 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy
NCT02930343 · Jawaharlal Institute of Postgraduate Medical Education & Research · PHASE3 · terminated · last registry update 2021-07-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Due to time constraints, the study was halted prematurely” | – | Registry record, Jawaharlal Institute of Postgraduate Medical Education & Research |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DHODH within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-05-23Phase 3 first posted: Biocad, BCD-132 + Teriflunomide (NCT05385744)
- 2022-04-19Results posted on the registry: Clear Creek Bio, Inc., Brequinar + Placebo (NCT04575038)
- 2022-02-16Results posted on the registry: Clear Creek Bio, Inc., Brequinar (NCT04425252)
- 2022-02-02Also stopped (terminated): PTC Therapeutics, PTC299 (NCT03761069)
- 2022-01-21Phase 3 first posted: Immunic AG, IMU-838 tablets + Placebo matching IMU-838 tablets (NCT05201638)
- 2021-12-14Phase 3 first posted: Novartis Pharmaceuticals, Remibrutinib + Teriflunomide (NCT05156281)
- 2021-12-07Phase 3 first posted: Novartis Pharmaceuticals, Remibrutinib + Teriflunomide (NCT05147220)
- 2021-12-06Results posted on the registry: TG Therapeutics, Inc., Ublituximab + Teriflunomide (NCT03277261)
- 2021-12-06Results posted on the registry: TG Therapeutics, Inc., Ublituximab + Teriflunomide (NCT03277248)
- 2021-11-26Phase 3 first posted: Immunic AG, IMU-838 tablets + Placebo matching IMU-838 tablets (NCT05134441)
- 2021-07-23Results posted on the registry: Immunic AG, IMU-838 (30 mg/day) + IMU-838 (45 mg/day) (NCT03846219)
- 2021-07-02Results posted on the registry: ASLAN Pharmaceuticals, ASLAN003 (NCT03451084)
- 2021-06-11Results posted on the registry: Actelion, ponesimod + teriflunomide (NCT02425644)
- 2021-06-02Results posted on the registry: Elizabeth Carey, Vidofludimus calcium (NCT03722576)
- 2021-03-09Phase 3 first posted: Novartis Pharmaceuticals, Ofatumumab + First line DMT (NCT04788615)
- 2020-11-30Results posted on the registry: Genzyme, a Sanofi Company, Teriflunomide + Placebo (NCT02201108)
- 2020-10-19Results posted on the registry: Novartis Pharmaceuticals, Ofatumumab subcutaneous injection + Teriflunomide-matching placebo capsules (NCT02792231)
- 2020-10-19Results posted on the registry: Novartis Pharmaceuticals, Ofatumumab subcutaneous injection + Teriflunomide-matching placebo capsules (NCT02792218)
- 2020-10-14Phase 3 first posted: Hoffmann-La Roche, Fenebrutinib + Teriflunomide (NCT04586010)
- 2020-10-14Phase 3 first posted: Hoffmann-La Roche, Fenebrutinib + Teriflunomide (NCT04586023)
- 2020-08-12Results posted on the registry: Northwestern University, Standard treatment with a conventional drug (NCT00273364)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision